Background and Purpose-National guidelines on carotid endarterectomy (CEA) for asymptomatic patients state that the procedure should be performed with a Յ3% risk of perioperative death or stroke. We developed and validated a multivariate model of risk of death or stroke within 30 days of CEA for asymptomatic disease and a related clinical prediction rule. Methods-We analyzed asymptomatic cases in a population-based cohort of CEAs performed in Medicare beneficiaries in New York State. Medical records were abstracted for sociodemographics, neurologic history, disease severity, diagnostic imaging data, comorbidities, and deaths and strokes within 30 days of surgery. We used multivariate logistic regression to identify independent predictors of perioperative death or stroke. The CEA-8 clinical risk score was derived from the final model. Results-Among the 6553 patients, the mean age was 74 years, 55% were male, 62% had coronary artery disease, and 22% had a history of distant stroke or transient ischemic attack. The perioperative rate of death or stroke was 3.0%. Multivariable predictors of perioperative events were female sex (odds ratio [OR]ϭ1.5; 95% CI, 1.1 to 1.9), nonwhite race (ORϭ1.8; 95% CI, 1.1 to 2.9), severe disability (ORϭ3.7; 95% CI, 1.8 to 7.7), congestive heart failure (ORϭ1.6; 95% CI, 1.1 to 2.4), coronary artery disease (ORϭ1.6; 95% CI, 1.2 to 2.2), valvular heart disease (ORϭ1.5; 95% CI, 1.1 to 2.3), a distant history of stroke or transient ischemic attack (ORϭ1.5; 95% CI, 1.1 to 2.0), and a nonoperated stenosis Ն50% (ORϭ1.8; 95% CI, 1.3 to 2.3). The CEA-8 risk score stratified patients with a predicted probability of death or stroke rate from 0.6% to 9.6%. Conclusions-Several sociodemographic, neurologic severity, and comorbidity factors predicted the risk of perioperative death or stroke in asymptomatic patients. The CEA-8 risk score can help clinicians calculate a predicted probability of complications for an individual patient to help inform the decision about revascularization. (Stroke. 2010;41:2786-2794.)
T hree quarters of the 117 000 carotid endarterectomies (CEAs) performed annually in the United States are for asymptomatic disease. 1 The overall magnitude of benefit of CEA in asymptomatic patients is modest. In randomized controlled trials (RCTs), CEA reduced the absolute risk of stroke or perioperative death among asymptomatic patients by Ϸ6% over 5 years compared with medical therapy alone. 2, 3 Because there was a 3% risk of death or stroke due to the procedure in the RCTs, national guidelines emphasize that the overall benefit of surgery for asymptomatic disease is critically dependent on perioperative risk. 4, 5 Patients with a Յ3% complication rate would benefit more, those with a Ͼ3% risk would benefit less, and for those at high operative risk, the risks might outweigh the benefits. Having an evidence-based way to calculate the personalized risk of CEA for an asymptomatic patient would help physicians counsel patients about the potential benefits and harms of carotid revascularization.
Unfortunately, no validated model for predicting perioperative complications of CEA in asymptomatic disease exists. Most previous studies of perioperative risk after CEA have several limitations. Most studies lacked multivariate analyses, 6 -9 or they focused on all-comers (symptomatic and asymptomatic patients), 6 ,10 -13 single institutions, 6,10 -13 inhospital complications, 7,8,14 -16 or highly selected surgeons and patients in the RCTs. [17] [18] [19] [20] [21] The few prior studies that proposed a clinical risk prediction rule for CEA were either developed in all-comers (symptomatic and asymptomatic patients) 22, 23 or symptomatic patients alone. 19, 21 Extrapolation about risk factors for asymptomatic patients from studies of symptomatic patients or all-comers is problematic for several reasons. Symptomatic patients have a greater severity of carotid disease, more comorbidities, and double the rates of perioperative death and stroke (6% vs 3%) compared with asymptomatic patients. 5, 9 The proportion of asymptomatic patients in all-comer studies has ranged from about one quarter 22 to three quarters. 1 This study sought to (1) develop and validate a multivariable model predicting the risk of death and stroke within 30 days of CEA for asymptomatic patients and (2) create a practical, clinical prediction rule that could be used by physicians and patients to weigh the risks and benefits of surgery.
Methods

Study Population
The New York Carotid Artery Surgery (NYCAS) Study included all Medicare beneficiaries who underwent a CEA (International Classification of Disease, ninth revision, code 38.12) in any hospital in New York State between January 1, 1998, and June 30, 1999. Details about NYCAS have been published previously. 1, 24 Cases were identified by using Medicare and New York State hospital discharge data. The study was approved by the University of Texas Southwestern Medical Center Institutional Review Board. Of 11 406 potentially eligible cases, medical records for 10 817 cases (94.8%) were reviewed. Among these, we excluded 110 cases with no CEA performed, 308 with same-side operations for restenosis, 490 with CEA combined with other procedures, and 601 lacking clinical risk factor data. Of 9308 complete cases, 6553 were performed on clinically defined asymptomatic patients.
Data Collection
Hospital charts were abstracted by trained nurse abstractors for sociodemographics, neurologic examination, functional status, laboratory values, medications, diagnostic imaging results, and neurologic, medical, and surgical histories. We calculated revised cardiac risk index 25 and Charlson comorbidity 26 scores. Severe disability was defined as a modified Rankin score of 4 to 5. Asymptomatic patients were defined as those with no history of carotid stroke or transient ischemic attack (TIA) Յ12 months before surgery. A history of distant cerebrovascular disease was defined as a stroke or TIA Ͼ12 months before surgery.
Carotid imaging data included the percent stenosis of the operated and nonoperated artery and the presence of plaque ulcers. Angiography was considered to be the most accurate imaging test, followed by Doppler ultrasonography and then magnetic resonance angiography. When no imaging results were available, stenosis information was abstracted from preoperative notes. Abstractors passed quality assurance tests, and interrater reliability was high (ϭ0.60 to 1.0).
Outcomes
We identified potential perioperative deaths, strokes, and TIAs by abstracting the medical records of the index admission, as well as the charts for readmissions to any hospital in the state within 30 days of surgery by using Medicare and New York State hospital discharge databases. Research nurses reviewed the admission and progress notes, discharge summaries, and brain imaging reports. Cases identified by the abstractors as having a death, stroke, or TIA were independently reviewed and confirmed by 2 physicians (including a neurologist). Initial agreement was 95%, and disagreements were resolved by consensus.
Analysis Plan
The primary outcome of interest was death or nonfatal stroke within 30 days of surgery, the composite outcome used in the RCTs and national guidelines. We also developed a risk model for the secondary outcome of all strokes (fatal and nonfatal) within 30 days of surgery. We first assessed univariate associations between outcomes and risk factors. Categorical variables were examined with 2 tests and Cochrane-Mantel-Haenszel tests for trend and continuous data, with t tests and Wilcoxon rank-sum tests, as indicated. Age was examined as a continuous variable, intervals, and thresholds (75 and 80 years old). Nonwhite refers to blacks and Hispanics. The other/unknown race group was very small and had outcomes similar to those of whites, so the data for these 2 race categories were combined. Univariate clinical predictors significant at the PϽ0.2 level were entered into a hierarchical multivariable logistic model. We used generalized estimating equations to account for the effects of clustering of patients by surgeon and surgeon by hospital. 27 We used cross-validation to examine the predictive power of the multivariable model by performing 100 iterations of a random 75%:25% split of the data into derivation and validation samples. 28 We further validated the risk model by plotting the observed rates of adverse events by quintile of predicted probability of events for the derivation and validation groups. Model discrimination was assessed with the c-statistic, and calibration was performed with the Hosmer Lemeshow test.
On the basis of the final multivariable model of death or stroke, we developed a clinical risk score in accordance with published principles. 29 Seven risk factors with similar standardized ␤ coefficients were assigned 1 point (female, nonwhite, congestive heart failure, coronary artery disease, valvular heart disease, cerebrovascular disease, and nonoperated stenosis Ն50%), and severe disability was assigned 2 points (because it had twice as large a ␤ coefficient). The total risk score ranged from 0 to 9 points. Given the small percentage of patients with Ն5 points (nϭ159, or 0.2% of the total), these cases were grouped as the highest risk group. Analyses were performed with SAS 9.2 (SAS, Cary, NC) and R 2.9.0 (Vienna, Austria).
Results
Patient Characteristics
NYCAS included 6553 CEAs performed on asymptomatic patients. Table 1 shows the patient characteristics. The meanϮSD age was 74.5Ϯ6.6 years (range, 42 to 98) and 54.9% were male. Nearly three quarters of patients had hypertension, 62.4% had coronary artery disease, 29.2% had diabetes, 13.4% had valvular heart disease, and 9.2% had congestive heart failure. With regard to neurologic history, 21.8% had a history of distant stroke or TIA, and 1.4% had severe neurologic disability. Nearly all patients (96.4%) had highgrade stenosis (70% to 99%). There was a wide range of stenosis on the nonoperated artery, with 37.1% having Ն50% contralateral stenosis and 5.6% having total occlusion. The CEAs were performed by 435 surgeons at 157 hospitals.
Univariate Predictors of Perioperative Outcomes
Within 30 days of surgery, there were 55 deaths (0.84%) and 165 (2.52%) strokes. The overall rate of combined perioperative death or nonfatal stroke was 3.05% (nϭ200). Table 1 shows the univariate predictors of adverse outcomes. Patients who were Ն80 years old had higher rates of death or stroke (3.81% vs 2.76%, PϽ0.03). Using a cutpoint of Ն75 years did not differentiate groups with significantly different outcomes. Women and nonwhites had significantly higher rates of death or stroke. Cardiovascular comorbidities like coronary artery disease, valvular heart disease, atrial fibrillation, and congestive heart failure also increased the risk of com- 
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plications, as did diabetes. The higher the overall comorbid illness burden, the higher the chance of death or stroke. Those with distant stroke or TIA also had worse outcomes (4.06% vs 2.71%). Severe disability greatly increased the risk of adverse events (10.75% vs 2.90%). The degree of stenosis of the operated artery was not significantly associated with outcome. However, those with Ն50% stenosis of the nonoperated artery or with ulcerated plaques had higher risks of death or stroke. Univariate predictors of stroke alone were similar to those for the combined outcome of death or stroke, with the exception of older age.
Multivariate Predictors of Perioperative Outcomes
Eight variables were independent predictors of death or stroke (Table 2) . Two were sociodemographics factors (female sex and nonwhite race), 3 were neurologic (history of distant stroke or TIA, nonoperated stenosis Ն50%, and severe disability), and 3 were cardiac comorbidities (coronary artery disease, congestive heart failure, and valvular heart disease). Neither age Ն75 nor age Ն80 years was a significant multivariate predictor; there was no interaction between older age and sex. Among comorbidities, diabetes was eliminated by the other cardiac conditions. Figure 1A shows that the final multivariable model of death and stroke performed similarly in both the derivation and validation analyses (c-statisticϭ0.64 and 0.62). The independent risk factors for any stroke were nearly identical to those for combined death and stroke, with the exception of congestive heart failure, which did not meet statistical significance for the any stroke model. Comparison of the final stroke model in the derivation and validation samples is shown in Figure 1B (c-statisticϭ0.65 and 0.64). Both multivariable models were well calibrated according to the Hosmer-Lemeshow test.
Clinical Risk Prediction Rule
We produced 2 clinical prediction rule versions of the final multivariable model. One version uses all 8 variables in the final model; each variable is worth 1 point except for disability, which is worth 2 points (Table 3 ). Figure 2A shows that the CEA-8 clinical risk score stratified patients from an observed death or stroke rate of 0.6% to 9.6%. On the basis of national guideline benchmarks (Յ3% death or stroke rate), patients with a score of 0 to 2 would be classified as low risk, those with 3 points as moderate risk (4.7%), and those with Ն4 points as high risk (7.5%). Based on this CEA-8 clinical risk score and the observed outcomes, 70.7% of patients in NYCAS were at low risk, 19.7% were at moderate risk, and 9.6% were at high risk. Based on predicted probability of complications, one quarter (26.5%) of patients had a higher predicted probability of death and stroke rate than the recommended national guideline (3% threshold). Figure 2B shows a "patient-friendly" CEA-7 version of the risk score that nonmedically trained individuals could use themselves to estimate their risk by using the simple sociodemographic (sex, race) and clinical information they know. The CEA-7 version omits "nonoperative stenosis Ն50%," based on the assumption that many patients might not know this detail. The 7-factor patient-friendly risk score also stratified the risk of adverse outcomes (1.4% to 8.3%).
Discussion
In this population-based study of 6553 asymptomatic patients undergoing CEA performed by 435 surgeons at 157 hospitals, we examined the potential impact of Ͼ26 patient and clinical characteristics on the risk of stroke or death within 30 days of CEA. The final multivariable model identified several sociodemographic, neurologic severity, and comorbidity factors that were independently associated with a higher risk of perioperative complications. Among sociodemographic factors, our finding that women had higher risk-adjusted odds of complications is consistent with prior studies. 30, 318 The higher risk in women may help explain why subgroup analyses of the RCTs and the metaanalyses found that asymptomatic women did not appear to benefit from CEA. 32 If women have higher upfront rates of death or stroke due to the procedure, it will be more difficult for them to accrue long-term benefits. The higher perioperative risk among nonwhite patients has been reported in most studies of all-comers undergoing CEA, although this has been attributed to higher rates of symptomatic disease among minorities. 14, [33] [34] [35] Finding such a disparity among asymptomatic persons implies that the differences are likely a function of a combination of patient, surgeon, and hospital factors. 35 Among the neurologic severity variables, 2 markers of underlying prior cerebrovascular disease (severe disability, and distant stroke or TIA) greatly increased the odds of adverse events, as did Ն50% contralateral stenosis. These neurologic severity variables have been found to increase risk in all-comer CEA populations. 9, 15, 24 In the Asymptomatic Carotid Atherosclerosis Study, both distant stroke and contralateral stenosis Ն60% were univariate predictors of 30-day death or stroke, although these analyses were not riskadjusted. 20 That the severity of ipsilateral stenosis was unrelated to short-term complications is consistent with the RCTs and meta-analyses that also found that long-term benefits from CEA in asymptomatic patients were similar in moderate and severe stenosis. 32 The presence of major cardiovascular problems (congestive heart failure, coronary artery disease, and valvular heart disease) as risk factors is consistent with the literature. 8,23,24,36, 37 We have previously identified predic- High risk Ն4 Ն4
NA indicates not applicable. tors of perioperative complications in all-comers in NYCAS (asymptomatic and symptomatic patients); this study focused on stratifying risk among the 6553 asymptomatic patients in the cohort. Both the all-comer and asymptomatic risk models included nonwhite race, distant stroke or TIA, nonoperated stenosis Ն50%, disability, and coronary artery disease as significant multivariables factors. 24 The clinical prediction rule version of the final risk models represents a new and practical contribution to the literature, as it is the first risk score focused on asymptomatic patients. Prior risk scores in CEA were either for all-comers (symptomatic and asymptomatic patients) 22, 23 or the select patients and surgeons in the symptomatic European Carotid Surgery Trial. 19 Whereas previous prediction rules were developed for different patient populations, our CEA-8 risk score shares some of the other indices: female sex, prior cerebrovascular disease, contralateral stenosis, coronary artery disease, and congestive heart failure (see Appendix Table 5 in the onlineonly Data Supplement, available at http://stroke.ahajournals. org, for details).
The CEA-8 risk score can help referring physicians, surgeons, neurologists, and anesthesiologists calculate the short-term risk of CEA in an individual patient. Because the absolute benefits of carotid revascularization among patients with asymptomatic disease is very modest (reduction of Ϸ1% risk of stroke per year), understanding the probability of upfront harm due to the procedure is critical to weighing its long-term net benefit for a given patient.
The RCTs and national guidelines stress the importance of having CEA performed by a surgeon and at a hospital with a Յ3% risk of death or stroke within 30 days. The good news from NYCAS was that the average 30-day death and stroke rate among asymptomatic patients having surgery in community practice was at the 3.0% benchmark. The cautionary news was that Ͼ1 in 4 Medicare patients had a predicted probability of perioperative events Ͼ3%. We envision clini- (8-factor version) . B, Observed rates of death or stroke within 30 days of CEA, according to the number of total risk points from the patient-friendly CEA-7 risk score (7-factor version).
cians using the CEA-8 risk score in the following fashion. Patients with 0 to 2 points would be classified as low risk, safely below the 3% guideline threshold. Those with 3 points, with a predicted 4.7% death and stroke rate, would be at moderate risk (slightly above the 3% threshold). Those with 4 points (with a Ն7.5% risk of serious complications) are at high risk, and CEA would unlikely be beneficial for most patients with this profile. The 7-factor patient-friendly CEA-7 risk score also clearly identifies low-, moderate-, and highrisk groups and could be used by patients themselves to help them make a shared, informed decision about surgery.
The strengths of the current study should be viewed in the context of several limitations. Whereas NYCAS collected detailed data on potential risk factors and outcomes from medical records, it was based on documentation in real-world practice. There was no prospective data collection or outcome examination, as done in the RCTs. However, clinical events were reviewed by 2 study investigators, and the richness of our data is much greater than in most prior studies of CEA risk factors. NYCAS reflects practice in 1 state, albeit a large one, during 1998 and 1999. Table 4 shows the perioperative outcomes and patient characteristics in NYCAS compared with the landmark RCTs and 2 very recent, large, observational cohort studies of CEA for asymptomatic disease. This shows that the outcome rates in NYCAS were comparable to those in RCTs 2,3 and similar to those reported among Medicare beneficiaries during 2004 to 2005. 38 It is worth noting, however, that a recent study by Woo et al 37 of asymptomatic patients of all ages undergoing CEA in the National Surgical Quality Improvement Program registry reported lower absolute rates of perioperative death and stroke. These differences are likely due to the fact that NYCAS Medicare patients were older and sicker than those in the National Surgical Quality Improvement Program, and voluntary registries tend to overrepresent high-performing institutions. The study by Woo et al also excluded patients with a distant history of stroke and TIA, which represented 21.8% of asymptomatic patients in NYCAS, a risk factor that increased the risk-adjusted odds of death or stroke by 48%. However, the applicability of our results to non-Medicare populations merits further investigation, and future work should include validation of the prediction rule in an independent, more contemporary sample.
It is also worth acknowledging that a patient's risk of surgical complications is a function of both their individual characteristics and the skill and experience of the surgeon and hospital team caring for them, 39 so both elements of risk should be factored in an evidence-based decision about revascularization. Ultimately, the decision about revascularization needs to weigh both the short-term risks of surgery against its long-term benefits. More research is needed with regard to developing evidence-based estimates of the longterm benefit of CEA for an individual asymptomatic patient.
In summary, although the rates of perioperative death and stroke after CEA in this population-based cohort were similar to those deemed optimal in the RCTs and national guidelines, the range of risk faced by asymptomatic patients undergoing surgery in community practice ranged from Ͻ1% to almost 10%. The new CEA-8 risk score that we developed can help physicians counsel patients about the potential risks and benefits of CEA and help rationalize selection of appropriate candidates. Further prediction rules that could help asymptomatic patients individualize the long-term benefits of CEA would be additionally valuable in improving overall decision making. 
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